I
InStride Health
Proven anxiety treatment when and where it’s needed most
About InStride Health
InStride Health is a digital health startup that provides evidence-based mental health care for children, teenagers, and young adults. The company operates in the Northeastern United States, offering services in seven states including Connecticut, Massachusetts, and New York. InStride's primary focus is on treating anxiety disorders and obsessive-compulsive disorder (OCD), which are among the most common pediatric mental health disorders.
Read full description
The company's business model is centered around a coordinated care approach, which involves a three-person team providing personalized treatment and support to each patient. This team includes clinical experts, exposure coaches, and peer support. The treatment is tailored to the individual's needs and intensity of treatment is adjusted as required.
InStride's services are delivered virtually, which adds flexibility and convenience for busy families. The company's virtual treatment model has been proven to be as effective as in-person treatment for anxiety and OCD.
InStride's services are covered by insurance, which removes a significant barrier to accessing traditional mental health care. The company's coordinated care model brings together therapy, medication management, and coaching, providing a comprehensive approach to mental health treatment.
The company was co-founded by two Harvard-trained professionals who previously co-founded the McLean Anxiety Mastery Program at McLean Hospital, a top-ranked psychiatric care institution in the United States.
Latest news
Press, funding announcements and product moves mentioning InStride Health.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jun 2026 | $30M | $120M | Echo Health Ventures · FMZ Ventures · .406 Ventures · General Catalyst | ↗ |
| SERIES BOther financing | Mar 2024 | $30M | $120M | .406 Ventures · Mass General Brigham Ventures · Valtruis · HopeLab | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for InStride Health is 37K monthly website visits, down 5.1% over the last three months. InStride Health's team grew 5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
.406 Ventures
Mass General Brigham Ventures
Valtruis
General Catalyst
HopeLab
Series B and later2 investors entered at this stage
Echo Health Ventures
FMZ Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InStride Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InStride Health’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.